Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy

Frontiers in Oncology

Joshua L. Owen¹  Marie Donaldson¹  Young K. Chae²  Jennifer N. Choi³ 

[1] Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States;Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States;Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, United States;

关键词: PD-1 inhibitor;    nivolumab;    lichenoid;    dermatitis;    immunotherapy;    phototherapy;   

DOI  :  10.3389/fonc.2018.00405

来源: DOAJ

【 摘 要 】

Immune checkpoint inhibitors targeting the programmed cell death receptor 1 (PD-1) are increasingly used to treat several malignancies, with the most common adverse event being cutaneous toxicity. We report the case of a 68-years-old man with stage IV non-small cell lung cancer treated with nivolumab who developed a pruritic, lichenoid eruption refractory to treatment with topical or systemic steroids, who was started on narrow band ultraviolet B therapy which resolved the reaction.

【 授权许可】

Unknown